IDEXX Laboratories, Inc.

IDXX Healthcare Diagnostics & Research

IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 9.66%, EPS grew 17.2%, free cash flow grew 111.4% and total debt fell 14.3%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three.

560.36 13.18 +2.41%
Market cap
$43.1B
P/E
39.1×
Fwd P/E
38.3×
Dividend yield
—
F-score
8/9
Altman Z
24.09
Beneish M
−2.50
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

64.63% 66.20% 72.92% 74.21%
Piotroski F-Score
8 8 8 9
ROA
30.50% 31.89% 33.19% 33.65%
ROIC
43.47% 45.33% 48.68% 48.87%
Return on Tangible Assets
106.50% 104.65% 122.43% 119.33%
Average Days of Receivables
49.65 46.85 49.55 50.27
Free Cash Flow per Share
10.78 11.89 13.28 15.67
Free Cash Flow
863.22 956.58 1,058.11 1,237.09
Other line items

Show all line items

Columns are period end dates